Login:
 
New oral anticoagulants have a good risk-benefit profile in atrial fibrillation.Practitioner 2014;258 (1768):9

New oral anticoagulants have a good risk-benefit profile in atrial fibrillation

24 Feb 2014Pais-up subscribers

The new oral anticoagulants are at least as good as, if not better than, warfarin at preventing strokes in patients with atrial fibrillation and have a lower rate of major bleeding, a large meta-analysis has found. The analysis, published in The Lancet, covered trials of atrial fibrillation patients who were randomised to new oral anticoagulants or warfarin, and in which both efficacy and safety outcomes were reported. A total of 71,683 patients in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials were included.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article